SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion (INFQ) is trending as excitement builds around its completed SPAC merger, with the company's CEO featured on financial news and plans to ring the NYSE opening bell, leading the community to discuss its undervalued neutral-atom quantum technology and significant partnerships with entities like NASA and NVIDIA.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce (CRM) is a central topic amid an aggressive sector-wide sell-off in enterprise software, driven by intense market speculation that generative AI will disrupt traditional SaaS models. While many bears highlight AI's transformative potential, a significant portion of the community views the stock as deeply undervalued, emphasizing its robust financials, strong free cash flow, and strategic position to integrate AI into its indispensable platform.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending after its latest earnings, which saw a beat on current quarter figures but a lowered profit outlook for upcoming periods, despite increased revenue guidance. This mixed report has sparked a sharp debate among investors, with some viewing the significant sell-off as an overreaction driven by broader software sector fears about AI, while others point to high valuations and M&A integration costs as justified concerns.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending due to Nvidia's latest filing revealing an exit from its APLD position, sparking panic selling and concerns about investor confidence. However, many in the community contend this is old news from Q4 2025 and a strategic move by Nvidia, arguing APLD's strong data center fundamentals and upcoming hyperscaler contracts remain intact.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Aldeyra Therapeutics is trending after the FDA extended the PDUFA date for its dry eye drug, Reproxalap, to March 2026, requesting additional data but having already shared a draft label and raising no new issues. This has split community sentiment between those who see it as a positive sign of likely approval, citing AbbVie's pre-launch activities, and others who remain wary due to prior rejections and a recent executive departure.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

CMPS is experiencing a significant surge following highly positive Phase 3 trial results for its COMP360 psilocybin therapy in treatment-resistant depression, with the company accelerating commercialization plans and seeking a rolling FDA submission. The community is actively debating the stock's long-term potential as a pioneer in psychedelic treatments, though a proposed public offering is generating concerns about dilution and short-term volatility.

American Superconductor Corp. engages in the provision of megawatt-scale power solutions. Its products include electric control systems, generators & drivetrains, power converters, renewable interconnectivity solutions, software, turbine designs, utility and industrial resilience and modernization solutions, and utility voltage solutions. It operates through the Grid and Wind segments. The Grid segment enables electric utilities and renewable energy project developers to connect, transmit, and distribute power with efficiency, reliability, security, and affordability. The Wind segment permits the manufacturers to field wind turbines with power output, reliability, and affordability. The company was founded by Yet Ming Chiang, David A. Rudman, John B. Vander Sande, and Gregory J. Yurek on April 9, 1987 and is headquartered in Ayer, MA.

American Superconductor Corp.

American Superconductor (AMSC) is drawing significant attention following robust financial results and strong guidance, as the community highlights its crucial role in modernizing energy grids and supplying essential infrastructure for power-hungry AI data centers. The stock is perceived as undervalued, with analysts raising price targets amid speculation of key strategic partnerships and expanding defense opportunities.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera (ATOM) is trending with record trading volume following its Q4 2025 earnings call, where management expressed strong confidence in securing near-term licensing and commercial agreements for its Mears Silicon Technology in advanced Gate-All-Around (GAA) and AI chip applications. The community is actively discussing the potential for significant power efficiency improvements in semiconductors and a possible short squeeze, despite historical skepticism surrounding its pre-revenue status.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending amidst highly divergent investor moves, with Warren Buffett's Berkshire Hathaway significantly cutting its stake while Bill Ackman's Pershing Square dramatically increased its position, sparking debate over its historic losing streak and heavy AI capital expenditures against strong AWS growth and perceived undervaluation.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line is trending as activist investor Elliott Management has taken a significant stake, sparking optimism in the community that their push for board and management changes will finally catalyze improved performance and allow the cruise operator to catch up with rivals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cibc World Market Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO

Cibc World Market Inc. acquired a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange...

<ul class="summary-bullets"><li>Biotech-focused investor Cormorant Asset Management rebuilt its stake above 6% on Tuesday.</li><li>Cormorant disclosed ownership of 4.36 million shares, up from about 2 million shares in October.</li><li>Retail sentiment flipped to ‘extremely bullish’ from ‘extremely bearish’ on Stocktwits, and message volume surged more than 900%.</li></ul>Shares of MoonLake Immunotherapeutics, Inc. jumped 11% on Tuesday, marking the stock’s biggest rally in over a month, after a biotech-focused investment firm rebuilt its stake amid heightened buzz among retail traders speculating a possible takeover.<h2 class="st-heading-2">Cormorant Lifts MoonLake Stake Above 6%</h2>A Schedule 13G filing on Tuesday showed Cormorant Asset Management reported ownership of 4.36 million Class A ordinary shares in MoonLake Immunotherapeutics, representing a 6.1% stake as of Dec. 31, 2025. The stake increased from about 2 million shares, or 3.14%, disclosed in October 2025 filings, after the firm had previously reduced its position below the 5% reporting threshold.Cormorant Asset Management is a biotech-specialised investment management firm with stakes in Praxis Precision Medicines, BridgeBio Oncology Therapeutics, Edgewise Therapeutics, and Metsera, which was acquired last year by Pfizer, among others.According to data from Quiver Quantitative, the firm reported holdings in 43 stocks as of Sept. 30, 2025, with an estimated portfolio value of about $1.45 billion.<h2 class="st-heading-2">FDA Momentum Builds Around Sonelokimab</h2>Earlier this month, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to the company’s lead investigational therapy, Sonelokimab, for moderate-to-severe palmoplantar pustulosis. The company plans to pursue a biologics license application for Sonelokimab in hidradenitis suppurativa in the second half of 2026.Last month, MoonLake said a Type B meeting with the FDA confirmed its clinical evidence strategy for Sonelokimab in hidradenitis suppurativa. Following that update, several brokerages raised price targets or upgraded the stock, though&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-erases-most-of-2025-loses-wall-street-retail-bets-on-fda-feedback-for-sonelokima/cmU1QhGR471">Goldman Sachs</a> downgraded MoonLake to ‘Sell’ last month, citing “high risk” around approvability in hidradenitis suppurativa.The company is scheduled to host an investor day on Feb. 23, at which it plans to provide updates on the clinical development and regulatory pathway for Sonelokimab across multiple inflammatory disease indications.<h2 class="st-heading-2">Stocktwits Buzz Erupts Around MLTX</h2>On Stocktwits, retail sentiment for MLTX flipped to ‘extremely bullish’ from ‘extremely bearish’ over the past day amid over a 900% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/mltx_ss_png_b0740594f9.webp" alt="mltx ss.png" width="971" height="140"><figcaption>MLTX sentiment and message volume as of February 17 | Source: Stocktwits</figcaption></figure>One user said the Cormorant filing has “fundamentally broken” the short thesis. “Cormorant—who knows the science better than anyone—just admitted the "Bear Thesis" was wrong by buying back in at $12-$16.”<stembedurl>https://stocktwits.com/septrading/message/645184471</stembedurl>Another user said, “I can’t stop thinking that we get a PR of some sort, even a little teaser, PM tomorrow AM” ahead of the company’s investor day.<stembedurl>https://stocktwits.com/BOOPIE2020/message/645177386</stembedurl>A third user said, “I have to say that something may be coming..This price action today was solid coupled with the high after hours volume. Someone is accumulating.”<stembedurl>https://stocktwits.com/TDMF123/message/645174457</stembedurl>A separate user said they were watching for either a buyout announcement or positive regulatory news this week, while another argued MoonLake would need to trade higher before attracting interest from a large pharmaceutical acquirer.<stembedurl>https://stocktwits.com/Warren_8/message/645090086</stembedurl><stembedurl>https://stocktwits.com/Newcar/message/645134185</stembedurl>One user pointed to recent travel activity involving Merck’s corporate jet, hinting at a potential takeover by the big pharma firm and noted multiple trips to Zurich, where MoonLake is headquartered.&nbsp;<stembedurl>https://stocktwits.com/Bigpapa46/message/645006814</stembedurl>MLTX stock has risen 33% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Equity

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $100.00

HC Wainwright upped their price objective on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday...

BridgeBio Pharma (NASDAQ:BBIO) Given New $83.00 Price Target at Oppenheimer

Oppenheimer boosted their price target on BridgeBio Pharma from $81.00 to $83.00 and gave the stock an "outperform" rating in a research note on Friday...

Wells Fargo & Company Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price

Wells Fargo & Company lifted their price target on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the stock an "overweight" rating in a research note on Friday...

BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the company's stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an...

BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week High - Here's What Happened

BridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month High - What's Next...

BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia

BridgeBio Pharma (NASDAQ:BBIO) detailed positive Phase 3 results from its PROPEL-3 clinical trial evaluating oral infigratinib for children with achondroplasia, describing what executives called...

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

Fundamental

Technical

A mix of both

Some investors focus on company fundamentals like earnings, growth, and valuation. Others rely on price action, trends, and momentum. Many use a combination of both to guide their decisions. What do you use?

What type of analysis drives your investment decisions?

Current Price	$75.85
Prev Close	$75.25
Open	$74.31
Dividend Yield	0.00%
50-Day Moving Average	$75.42
Beta	1.31
Avg. Volume	2.99M
PE Ratio	-17.97

52-Week High	$84.94
52-Week Low	$28.33
Market Capitalization	$14.97B
EPS (Annual)	-$2.88
Price to Book	-7.50
Revenue Per Employee	$303,975.34

BBIO
BridgeBio Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BBIO News

BBIOBridgeBio Pharma Inc